

## Economic Burden of AMD

Country	Year Published	Currency	Health System Costs		Productivity Losses		Carer Costs		Other Indirect Costs		Total Financial Costs	
			Total (million)	Per person with AMD	Total (million)	Per person with AMD	Total (million)	Per person with AMD	Total (million)	Per person with AMD	Total (million)	Per person with AMD
Global <sup>i</sup> (all AMD)	2012	USD	254.8 billion	6953 <sup>#</sup>	34.3 billion	936	23.3 billion	636	NA	0.3 trillion	8500	
Australia <sup>ii</sup>	2011	AUD	359.1	3350 <sup>#</sup>	18.7	175	47.5	443	323.0	748.4	6982	
New Zealand <sup>iii</sup>	2016	NZD	56.5	2849 <sup>#</sup>	18.5	931	0.7	33	14.0	89.6	4521	
Mexico <sup>iv</sup> (NVMD)	2013	EUR	43.5	376 <sup>*</sup>	3.4	29	15.2	131	NA	62	539	
Ireland <sup>v&amp;</sup>	2011	EUR	See Footnote &									
Canada <sup>vi</sup>	2009	CAD	898.9	10072 <sup>#</sup>	484	5423	76	851	226	1684	18878	
Italy <sup>vii</sup>	2013	EUR	248.6	1541								
Canada <sup>viii</sup> (NVMD)	2008	EUR	NA	1657 <sup>*</sup>								
France <sup>v</sup> (NVMD)	2008	EUR	NA	967 <sup>*</sup>								
Germany <sup>v</sup> (NVMD)	2008	EUR	NA	1514 <sup>*</sup>								
Spain <sup>v</sup> (NVMD)	2008	EUR	NA	683 <sup>*</sup>								
U.K. <sup>v</sup> (NVMD)	2008	EUR	NA	597 <sup>*</sup>								
United <sup>ix</sup> States	2013	USD	4.6 billion	3740 <sup>#</sup>	3.1 billion	1727	NA	NA	1.6 billion	9.3 billion	5287	

# Per person with vision loss due to AMD

\* Per person with NVMD

& Not possible to disaggregate AMD costs from total cost of vision loss

## Economic Burden of AMD

- i. Gordoys A, Cutler H et al, An estimation of the worldwide economic and health burden of visual impairment. *Global Pub Health* 2012;7:465-481.
- ii. Deloitte Access Economics 2011, 'Eyes on the Future: A clear outlook on Age-related Macular Degeneration', Deloitte Access Economics, Canberra. Available at: [https://www.mdfoundation.com.au/sites/default/files/Deloitte\\_Eyes\\_on\\_the\\_Future\\_Report\\_web\\_1\\_0.pdf](https://www.mdfoundation.com.au/sites/default/files/Deloitte_Eyes_on_the_Future_Report_web_1_0.pdf) Accessed 6 August 2017
- iii. Deloitte Access Economics 2016, Socioeconomic costs of macular degeneration in New Zealand, report conducted for Macular Degeneration New Zealand. Available at: <http://www.mdnz.org.nz/assets/Deloitte-MDNZ-Cost-of-AMD-FINAL-17-Oct-2016.pdf> Accessed 6 August 2017
- iv. Deloitte Access Economics 2013, The economic cost and burden of eye diseases and preventable blindness in Mexico, Deloitte Access Economics, Canberra. Available at: <https://www2.deloitte.com/content/dam/Deloitte/au/Documents/Economics/deloitte-au-economics-cost-eye-diseases-280314.pdf> Accessed 6 August 2017
- v. Deloitte Access Economics 2011. The economic impact of vision impairment and blindness in the Republic of Ireland. National Council for the Blind of Ireland. Available at: [http://www.eyedoctors.ie/documents/Cost\\_of\\_Sight\\_Loss\\_Full\\_Repor.pdf](http://www.eyedoctors.ie/documents/Cost_of_Sight_Loss_Full_Repor.pdf) Accessed 6 August 2017.
- vi. Cruess AF, Gordon KD et al. The cost of vision loss in Canada 2. Results. *Can J Ophthalmol* 2011;46:315-318
- vii. Deloitte Access Economics 2013, The economic cost and burden of eye diseases and preventable blindness in Italy, Deloitte Access Economics, Canberra. Available at: [www.iapb.it/fileutente/.../EFAB\\_slides\\_Deloitte\\_Access\\_Economics-20\\_Set1\\_2013.ppt](http://www.iapb.it/fileutente/.../EFAB_slides_Deloitte_Access_Economics-20_Set1_2013.ppt). Accessed August 6, 2017
- viii. Cruess AF, Zlateva G et al. Economic burden of bilateral neovascular age-related macular degeneration. Multi-country observational study. *Pharmacoeconomics* 2008;26:57-73
- ix. Wittenborn J, Rein D. Cost of vision problems. The economic burden of vision loss and eye disorders in the United States. Available at: <http://costofvision.preventblindness.org/costs>. Accessed 6 August 2017.